Related by context. All words. (Click for frequent words.) 84 RECIST criteria 79 Response Evaluation Criteria 79 RECIST Response Evaluation Criteria 78 Solid Tumors RECIST 72 evaluable patients 69 CR CRu 68 patients evaluable 67 remission CR 67 evaluable 67 Solid Tumors criteria 66 Partial Responses 66 CCyR 64 partial remissions 64 CRp 64 Partial Response 64 Solid Tumours 63 Solid Tumors 63 pCR 63 neoadjuvant chemotherapy 63 mg/m2 dose 62 complete cytogenetic 62 EBMT criteria 62 DAS# CRP 62 Kaplan Meier analysis 62 cytogenetic response 62 preoperative chemotherapy 62 neoadjuvant therapy 61 lymphocytosis 61 DAS# remission 61 chemoradiotherapy 61 ovarian cancer biomarker 61 FDG-PET/CT 61 biochemical relapse 61 CR nPR 61 progression TTP 61 Rate ORR 61 debulking surgery 61 localized renal 60 PSADT 60 locoregional recurrence 60 response CCyR 60 biochemical recurrence 60 ACR Pedi 60 renal tumors 60 complete remissions 60 locoregional disease 60 TIMP 1 60 bortezomib refractory 60 tumor shrinkage 60 free survival PFS 60 chlorambucil 60 underwent resection 60 splenectomized patients 60 sustained virological response 60 achieved CCyR 60 Doxil ® 59 undetectable HBV DNA 59 HBeAg seroconversion 59 nodular partial response 59 FOLPI 59 DAS# [002] 59 Free Survival PFS 59 MCyR 59 differentiated thyroid 59 pT2 59 breast carcinoma 59 undetectable HCV RNA 59 tumor recurrence 59 distant metastasis 59 pancreatic adenocarcinoma 59 F FDG PET 59 NIHSS 59 EDSS score 59 VGPR 59 Complete Response CR 59 prospectively defined 59 cEVR 58 Kaplan Meier 58 CDAI 58 Kaplan Meier method 58 Crohn Disease Activity 58 metastatic GIST 58 recurrent glioblastoma multiforme 58 Kaplan Meier estimates 58 SUVmax 58 Index CDAI 58 plus dexamethasone 58 virologic responses 58 leukocyte count 58 pegylated interferon alfa 2b 58 baseline LDH 58 median PFS 58 median survivals 58 achieved sustained virologic 58 #F FDG PET 58 FOLFOX6 58 radical nephrectomy 58 Secondary endpoints include 58 PSA nadir 58 chest radiographs 58 Kaplan Meier estimate 58 heavily pretreated 58 stage IIIA 58 preoperative PSA 58 % CI #.#-#.# [007] 58 antibody titer 58 Scale EDSS 58 Secondary endpoints 58 gemcitabine carboplatin 57 CRu 57 histopathologic 57 achieved ACR# 57 SVR# 57 timepoints 57 HBeAg positive patients 57 Pharmacokinetic parameters 57 definite stent thrombosis 57 neoadjuvant 57 mCi 57 chemoradiation therapy 57 R0 resection 57 neoadjuvant treatment 57 ACR# response 57 estimated GFR 57 ACC AHA 57 intact parathyroid hormone 57 clinically meaningful improvement 57 heavily pretreated patients 57 recurrent GBM 57 thymoma 57 mRCC 57 histologic 57 prospectively stratified 57 XELOX 57 mg kg dose 57 QRS duration 57 KRAS mutations occur 57 % Confidence Interval 57 complete cytogenetic response 57 secondary efficacy endpoint 57 FOLFOX4 57 viral kinetics 57 Secondary endpoints included 57 locoregional 57 FOLFOX 57 ertapenem 57 relapsed MCL 57 achieved sustained virological 57 XIENCE V PROMUS Stent 57 metastatic malignant 57 pT3 56 rFVIIa 56 VATS lobectomy 56 mg/m2/day 56 postoperative chemotherapy 56 follicular lymphomas 56 KRAS status 56 cinacalcet 56 cytoreduction 56 hepatectomy 56 prespecified secondary 56 % CI #.#-#.# [003] 56 serum HCV RNA 56 modified RECIST criteria 56 #Gy 56 CIMZIA TM 56 Severity MSCS score 56 epithelial ovarian cancer 56 PASI scores 56 thyroglobulin 56 PCWP 56 annualized relapse 56 Visual Analogue Scale VAS 56 epithelial tumors 56 tumor regression 56 chemoradiation 56 severe neutropenia 56 MACCE 56 TACE 56 ug kg 56 multivariate Cox 56 DLTs 56 log# reduction 56 stage IIIB 56 metachronous 56 mCRC patients 56 NMIBC 56 melphalan prednisone 56 Score TOS 56 Bezielle 56 CIMZIA ™ 56 IIIB NSCLC 56 lymphadenectomy 56 Expanded Disability Status 56 Flu Cy 56 Median progression 56 octreotide LAR 56 KRAS wild 56 CSBM 56 univariate 56 IL#B 56 radiotherapy RT 56 peginterferon alfa 2a #KD 56 ErbB2 positive 56 PRECiSE 56 tumor regressions 56 sipuleucel T 56 papillary renal cell carcinoma 56 microbiological eradication 56 oral diclofenac 56 Natalizumab 56 ACR# responses 56 carboplatin paclitaxel 56 Secondary efficacy endpoints 56 placebo dexamethasone 56 mITT population 56 axillary dissection 56 metastatic renal cell carcinoma 56 ZACTIMA 56 mcg albinterferon alfa 2b 56 Follicular Lymphoma 56 adjuvant GIST 55 -#.# log# 55 CIN2 + 55 5-fluorouracil/leucovorin 55 T1a 55 nab paclitaxel 55 IV NSCLC 55 Severity Index PASI 55 histologically proven 55 PEG IFN 55 TNM staging 55 transvaginal sonography 55 intermittent dosing 55 QTcF 55 HER2 positive cancers 55 crizotinib PF # 55 TLUS 55 postoperative complication 55 logistic regression analysis 55 Folfox 55 mycophenolate mofetil 55 Median PFS 55 Ejection Fraction 55 oncologic outcomes 55 ImmuKnow assay 55 xenograft models 55 genotypic resistance 55 FOLFIRI 55 azacytidine 55 Mean Symptom Complex 55 liver metastases 55 CMV disease 55 iniparib BSI 55 peg IFN 55 fluoropyrimidine 55 platinum refractory 55 composite endpoint 55 myocardial viability 55 liver transplant recipients 55 histologically confirmed 55 dosage regimens 55 CLL SLL 55 mg ustekinumab 55 squamous histology 55 detectable HCV RNA 55 mg BID dose 55 adjuvant chemotherapy 55 relapsed MM 55 methotrexate monotherapy 55 etiologic 55 adjuvant therapies 55 MabCampath 55 mucosal healing 55 FLT3 ITD 55 Fludara 55 efficacy evaluable 55 concurrent chemoradiation 55 % CI #.#-#.# [005] 55 lymph node metastasis 55 metastatic lesions 55 prespecified 55 pegylated liposomal doxorubicin 55 evaluable subjects 55 sUA 55 HIV RNA 55 antiangiogenic therapy 55 mcg kg 55 morphometric vertebral fractures 55 SSc patients 55 p = #.# [003] 55 CTEPH 55 μg kg 55 tPSA 55 oral Hycamtin 55 gefitinib Iressa 55 surrogate endpoint 55 5-FU/LV 55 gastric adenocarcinoma 55 hepatitis C genotype 55 FDG PET imaging 55 DLQI 55 metastatic malignant melanoma 55 rituximab refractory 55 TURBT 55 telaprevir dosed 55 percutaneous biopsy 55 recanalization 55 thyroid carcinoma 55 atheroma volume 55 microbiologically evaluable 54 operable breast cancer 54 prognostic significance 54 STRIDE PD 54 immunostaining 54 metastatic CRC 54 statistical significance p 54 serum urate 54 nonoperative 54 peg interferon 54 multivariate regression analysis 54 carcinoid 54 HER2 expression 54 peginterferon alpha 54 #mg dose [002] 54 sarcomatoid 54 ischemic cardiomyopathy 54 Multivariate analysis 54 ribavirin RBV 54 secondary endpoint 54 intraobserver 54 conditional logistic regression 54 Prognostic Index 54 glomerular filtration 54 μg dose 54 CHOP chemotherapy 54 surgical debulking 54 cytoreductive surgery 54 dosing cohorts 54 fludarabine cyclophosphamide 54 huN# DM1 54 intraperitoneal chemotherapy 54 estimated glomerular filtration 54 -#.# log# copies mL 54 EDSS scores 54 lopinavir r arm 54 Primary endpoints 54 nondiabetic patients 54 lymphocyte count 54 comparator arm 54 primary patency 54 BEACOPP 54 HOMA IR 54 ACTEMRA TM 54 iPTH 54 nodal metastases 54 confirmed CCyR 54 teriflunomide 54 nonmetastatic 54 EORTC 54 neurologic progression 54 ALND 54 Median survival 54 Psoriasis Area 54 malignant neoplasm 54 postoperative radiotherapy 54 Papillary 54 dose cohort 54 μmol L 54 nodal metastasis 54 standard chemotherapy regimen 54 nomograms 54 icatibant 54 EDSS 54 chemo radiotherapy 54 generalized edema 54 liposomal doxorubicin 54 dasatinib 54 adalimumab 54 sustained virologic response 54 SBRT 54 lung metastases 54 noninferiority 54 cGy 54 salmeterol fluticasone propionate 54 resected pancreatic cancer 54 MGd 54 EBRT 54 posaconazole 54 radiochemotherapy 54 previously untreated follicular 54 macroalbuminuria 54 Stage IIB 54 T#I [002] 54 mitoxantrone 54 curative resection 54 RGT arm 54 ug dose 54 logistic regression models 54 immunohistochemical analysis 54 pertuzumab 54 cardiac dysfunction 54 troponin T 54 cytogenetic responses 54 radical prostatectomy RP 54 apremilast 54 mg QD 54 ribavirin therapy 54 Aptivus ® 54 mcg dose 54 q#d 54 advanced adenoma 54 PSMA ADC 54 pomalidomide 54 posttreatment 54 PegIFN RBV 54 transthoracic 54 HRCT 54 graft occlusion 54 seroprotection 54 ICD implantation 54 bendamustine 54 ipsilateral stroke 54 Trastuzumab 54 endoscopic remission 54 pegylated alpha interferon 54 Cardiorespiratory fitness 54 malignant pleural mesothelioma 54 distant metastases 54 IMGN# 54 pmol L 54 peginterferon 54 tipranavir ritonavir 54 Score DAS# 54 alicaforsen enema 54 mesalamine granules 54 renal cell carcinomas 54 PROCHYMAL 54 Ceplene/IL-2 54 DAPT 54 bacillus Calmette Guerin 54 clinicopathological features 54 antibody titers 54 elevated ALT 54 liver histology 54 repigmentation 54 BCIRG 54 GSTP1 54 lung metastasis 54 ZOLINZA 54 histological subtype 54 radiographic progression 54 interferon ribavirin 54 postoperative mortality 54 nonresponders 54 angiographic outcomes 54 HoLEP 54 HBeAg negative patients 54 DMARD 53 NSABP B 53 pelvic lymphadenectomy 53 nomogram 53 colorectal liver metastases 53 TRUS 53 clinically meaningful improvements 53 ULORIC 53 binary restenosis 53 tumor histology 53 cisplatin vinorelbine 53 virologic response 53 oral allopurinol 53 VELCADE melphalan 53 anemia hemoglobin 53 BRIM2 53 Brief Psychiatric 53 lumiliximab 53 point Likert scale 53 hepatocellular carcinoma 53 logistic regression analyzes 53 node metastases 53 visceral metastases 53 decitabine 53 oral FTY# 53 tipranavir r 53 LV dysfunction 53 platelet reactivity 53 MDRD 53 colectomy 53 gastroduodenal 53 glomerular filtration rate 53 8mg/kg 53 plasma uric acid 53 Thrombolysis 53 galiximab 53 haematologic 53 tumor resection 53 pharmacodynamic effects 53 myocardial necrosis 53 Elitek 53 Allovectin 7 ® 53 prognostic indicator 53 seroconversion 53 SSc 53 postop 53 chemotherapy docetaxel 53 Tumor shrinkage 53 MADRS score 53 alanine aminotransferase ALT 53 HSCT 53 ACR# [002] 53 wedge resection 53 clinicopathological 53 gefitinib 53 seropositivity 53 LEXIVA r 53 BENICAR HCT 53 recurrent NSCLC 53 daunorubicin 53 Subgroup analyzes 53 ibandronate 53 Cancer Incidence Mortality 53 febrile neutropenia 53 Histologic 53 ovarian carcinoma 53 vandetanib 53 #.#ng/ml 53 EGFR mutation positive 53 FluCAM arm 53 dose escalation 53 infarct size 53 K DOQI 53 virological response 53 hemodynamic variables 53 glycated hemoglobin levels 53 Surgical resection 53 papillary 53 gastrointestinal stromal tumors 53 Taxotere ® 53 BENICAR 53 brain metastases 53 pharmacodynamic PD 53 colorectal carcinoma 53 ixabepilone 53 mcg QD 53 4mg/kg 53 invasive aspergillosis 53 perioperative complications 53 postprocedure 53 HCV RESPOND 2 53 erythrocyte sedimentation rate 53 tumor progression TTP 53 mg BID 53 Hamilton Anxiety Scale 53 IFN α 53 dose escalation phase 53 HGPIN 53 antitumor effect 53 K ras mutations 53 autologous SCT 53 adjuvant cisplatin 53 mcg doses 53 nonoperative treatment 53 ARB telmisartan 53 histopathological 53 pegylated interferon alfa 53 Operative mortality 53 serologically active patients 53 doxorubicin docetaxel 53 HBeAg negative 53 pancreatic carcinoma 53 p = NS 53 mL/min/#.# m 2 53 tumor xenograft models 53 alteplase 53 gastrointestinal stromal tumor GIST 53 radioiodine therapy 53 clinicopathologic 53 anaplastic astrocytoma AA 53 cervical carcinoma 53 NIH CPSI 53 CANCIDAS 53 carcinoid tumors 53 axitinib 53 microvessel density 53 dacarbazine chemotherapy 53 DSM IV diagnoses 53 oblimersen 53 peginterferon alfa 2a 53 corticosteroid dose 53 hepatic cirrhosis 53 cabazitaxel 53 FOLFIRINOX 53 Skin sterol 53 GLIADEL R Wafer 53 Timed Walk 53 multivariate analyzes 53 Castration Resistant Prostate Cancer 53 p# biomarker 53 carotid stenosis 53 ximelagatran 53 APPRAISE 53 LUX Lung 53 PROMACTA 53 KRAS mutations 53 hemagglutination inhibition 53 mcg BID 53 baseline FEV 53 HER2 positive metastatic breast 53 conventional IMRT 53 amoxicillin clavulanate 53 null responders 53 Zometa hazard 53 TIMP 53 T1c 53 ADPKD 53 estramustine 53 cytogenic 53 mCi kg 53 STN stimulation 53 Adjuvant chemotherapy 53 HUMIRA achieved PASI 53 Peg IFN 53 reflux esophagitis 53 LVEF 53 5FU 53 Virologic 53 ruboxistaurin 53 lateral radiographs 53 RoACTEMRA 53 NNT = 53 TMC# r 53 recurrent metastatic 53 Hycamtin ® 53 gemcitabine cisplatin 53 piperacillin tazobactam 53 seminal vesicle invasion 53 semiquantitative 52 DOXIL 52 univariate analysis 52 mutated KRAS 52 creatinine clearance 52 relapsing multiple sclerosis 52 lymph node involvement 52 achieved statistical significance 52 Carotid Revascularization Endarterectomy vs. 52 intima media thickness 52 sirolimus stent 52 multivariable logistic regression 52 randomized multicenter trial 52 hepatic lesions 52 completely resected 52 inotropic 52 interrater reliability 52 transcranial Doppler ultrasound 52 colorectal adenoma 52 orthotopic 52 certolizumab 52 KRAS mutation 52 NYHA functional class 52 preoperatively 52 ACR# ACR# 52 eGFR 52 hip resurfacing arthroplasty 52 cTnT levels 52 FDG PET scans 52 perioperative mortality 52 pancreatic neuroendocrine tumors 52 log# copies mL 52 Doppler sonography 52 microalbuminuria 52 irinotecan chemotherapy 52 relapsed multiple myeloma 52 mucinous 52 mcg Albuferon 52 RTOG 52 retrospective cohort 52 #mg QD [002] 52 DCE MRI 52 predefined criteria 52 serum cortisol 52 Montgomery Åsberg Depression 52 graft dysfunction 52 adjuvant therapy 52 urine albumin 52 virologic failure 52 androgen blockade 52 GOUT 52 interquartile range 52 metastatic RCC 52 bone metastasis 52 mg/m2 52 Radiographic 52 randomized Phase III 52 echocardiographic 52 gemcitabine chemotherapy 52 imipenem 52 doxorubicin cyclophosphamide 52 PegIFN 52 â ‰ ¥ 52 rapid virological response 52 prostate cancer PCa 52 myocardial revascularization 52 dacarbazine 52 extracapsular extension 52 airway hyperresponsiveness 52 nasal symptom 52 transaminases 52 ANOVA 52 X ULN 52 tanespimycin 52 pretreatment serum 52 Radical prostatectomy 52 EGFR expressing mCRC 52 immunosuppressive regimen 52 elevated transaminases 52 A1c levels 52 serum HBV DNA 52 transgene expression 52 ASCUS 52 refractory NSCLC 52 cervical lymph nodes 52 surgically resected 52 small lymphocytic lymphoma 52 tirofiban 52 infliximab 52 pain palliation 52 achieving sustained virologic 52 cisplatin gemcitabine 52 Visual Analog Scale 52 multicenter randomized controlled 52 EGFR mutations 52 statistically significant p = 52 splenectomized 52 nonsmall cell lung cancer 52 OvaRex MAb 52 NATRECOR R 52 coronary stenosis 52 REYATAZ r arm 52 cytogenetic abnormalities 52 Aflibercept 52 palliative radiotherapy 52 rFSH 52 adenoma recurrence 52 MitraClip device 52 node dissection 52 NOXAFIL 52 achieved PASI 52 boosted protease inhibitor 52 interferon alfa 52 thromboembolic events 52 treat NNT 52 multivariate logistic regression 52 adjuvant radiation 52 basal cell carcinoma BCC 52 dosing cohort 52 EGFR TKI 52 sunitinib 52 cutaneous melanoma 52 serum phosphorus 52 FluCAM 52 HAQ DI 52 oral ridaforolimus 52 oxycodone CR 52 Pemetrexed 52 auto allo 52 scintigraphic 52 hematologic toxicity 52 chest radiography 52 ACTEMRA 52 transcranial Doppler 52 zalutumumab 52 Mantel Haenszel 52 prospective multicenter study 52 low dose cytarabine 52 treatment naive genotype 52 desvenlafaxine succinate 52 postmenopausal osteoporotic women 52 sirolimus eluting stents 52 pituitary adenomas 52 plus prednisone 52 Virulizin ® 52 lactate dehydrogenase LDH 52 bronchial hyperresponsiveness 52 PAOD 52 CIMZIA TM certolizumab pegol 52 Halaven 52 Logistic regression 52 receiving highly emetogenic 52 Disease Activity 52 Metastatic breast cancer 52 Descriptive statistics 52 severe exacerbations 52 cancer mCRC 52 clodronate 52 collagenous colitis 52 nilotinib 52 confidence interval #.#-#.# 52 cisplatin chemotherapy 52 hematopoietic cancers 52 lesional 52 MGUS 52 LDB CPR 52 allogeneic SCT 52 SABCS 52 metastatic neuroendocrine tumors 52 ER CHOP 52 GAMMAGARD 52 Cotara 52 eplerenone 52 metastatic renal cell 52 gout flares 52 relapsed SCLC 52 HCV SPRINT 52 multivariable analysis 52 PITX2 methylation 52 prior relapsers 52 colorectal adenocarcinoma 52 YERVOY 52 INCB# [003] 52 seliciclib 52 ROSC 52 mL/min/#.# m2 52 ALT elevation 52 microdebrider 52 docetaxel Taxotere ® 52 MAGE A3 ASCI 52 Neoadjuvant 51 Postoperatively 51 stage IIIb IV 51 histologic findings 51 neoplasm 51 stent implantation 51 #mg BID [001] 51 clinically localized prostate 51 IU mL 51 achieve sustained virologic 51 receiving VICTRELIS 51 Cardiopulmonary bypass 51 MetS 51 Angiographic 51 SCr 51 logistic regression model 51 ispinesib administered 51 acetabular fractures 51 Interrater reliability 51 RE LY ® 51 pegIFN 51 contrast induced nephropathy 51 atherosclerotic renal artery stenosis 51 glufosfamide 51 docetaxel pretreated 51 histologies 51 Xanafide 51 imiquimod 51 doublet chemotherapy 51 sentinel lymph node biopsy 51 IRX 2 51 Randomized clinical trials 51 angiographically 51 asymptomatic carotid stenosis 51 bevacizumab 51 Erlotinib 51 NIHSS score 51 HNSCC 51 Index CDAI score 51 microg 51 interferon beta therapy 51 intraclass correlation coefficient 51 PREZISTA r arm 51 satraplatin Phase 51 prior chemotherapy regimens 51 Hodgkin lymphoma HL 51 hemoglobin A1c levels 51 ara C 51 multiple myeloma MM 51 cytoreductive nephrectomy 51 brivaracetam 51 prospective multicentre 51 ADAGIO study 51 albumin excretion rate 51 Health Assessment Questionnaire 51 cholangiocarcinoma 51 obstructive CAD 51 Engerix B 51 prostate cancer CaP 51 invasive carcinomas 51 paraprotein 51 rimonabant #mg/day 51 ezetimibe simvastatin 51 elevated LDH 51 liver metastasis 51 BI RADS 51 Elastography 51 EXJADE 51 DXA scan 51 TAXUS Express Stent 51 MoxDuo TM IR 51 LPV r 51 PsA 51 advanced adenomas 51 EURIDIS 51 T2 lesions 51 extracranial 51 ADAS cog 51 LV ejection fraction 51 adverse cytogenetics 51 antiretroviral naïve 51 #mg/m# [001] 51 docetaxel chemotherapy 51 -#.# ± [002] 51 mitomycin 51 pg mL 51 #m Tc 51 CsA 51 bladder carcinoma 51 CC genotype 51 radiologically 51 adrenalectomy 51 androgen ablation 51 postoperatively 51 colorectal carcinomas 51 Scale EDSS score 51 antithymocyte globulin 51 FOLFIRI alone 51 SIR Spheres 51 follicular lymphoma 51 clinically meaningful 51 topotecan 51 vismodegib 51 leukemia CLL 51 MVax 51 Irinotecan 51 HORIZONS AMI trial 51 Y BOCS 51 intravenous dosing 51 goserelin 51 GISTs 51 pharmacokinetic parameters 51 Unified Parkinson Disease 51 CLARITY study 51 pancreatic islet cell 51 prognostic factor 51 mITT 51 Acute Myeloid Leukaemia AML 51 Platelet counts 51 calculated creatinine clearance 51 prostate carcinoma 51 perioperatively 51 confidence interval CI 51 APTIVUS r 51 somatostatin analog 51 postintervention 51 antitumor activity 51 tracheal intubation 51 IQR 51 HDRS 51 vidofludimus 51 nonrandomized 51 EDEMA4 trial 51 Acute renal failure 51 IBDQ 51 follicular NHL 51 paragangliomas 51 FOLFOX regimen 51 laparoscopic radical nephrectomy 51 Velcade bortezomib 51 XIENCE V demonstrated 51 adjunctive placebo 51 myocardial infarctions MIs 51 Dacogen injection 51 baseline HbA1c 51 EGFR mutant 51 phase IIb study 51 leukemia AML 51 #mg/day [002] 51 uveal melanoma 51 biliary tract cancer 51 plus gemcitabine 51 unresectable tumors 51 response pCR 51 adjuvant systemic 51 lymphovascular invasion 51 undetectable viral load 51 HbA1C 51 oocytes retrieved 51 % CI #.#-#.# [001] 51 anti leukemic 51 COPEGUS 51 adriamycin 51 TroVax ® 51 cTnI 51 corrected QT interval 51 GFT# 51 induction regimen 51 bortezomib 51 Cystatin C 51 ADCS CGIC 51 vincristine doxorubicin 51 limiting toxicity